Want to see PCRX full AI Analyst Report?
PCRX Stock Chart & Stats
$25.88
$0.68(2.63%)
At close: 4:00 PM EDT
$25.88
$0.68(2.63%)
Day’s Range― - ―
52-Week Range$18.80 - $27.66
Previous CloseN/A
Volume164.31K
Average Volume (3M)495.81K
Market Cap
$983.39M
Enterprise Value$1.18K
Total Cash (Recent Filing)$251.03M
Total Debt (Recent Filing)$412.12M
Price to Earnings (P/E)70.6
Beta0.63
Next Earnings
Oct 29, 2026EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding39,861,885
10 Day Avg. Volume533,261
30 Day Avg. Volume495,814
Financial Highlights & Ratios
PEG Ratio-1.51
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$28.80Price Target Upside11.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)2.91
Revenue Forecast (FY)$754.02M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And LiquidityReliable cash generation gives Pacira flexibility to fund clinical development, support commercialization and reduce debt. The $251 million cash and investments balance, plus the Zimmer upfront payment, strengthens resilience while the portfolio evolves.
Expanding Payer AccessBroader reimbursement can lower adoption barriers and support durable utilization across hospitals and outpatient providers. UnitedHealthcare access also improves the commercial position of both key products and may expand procedure-level demand over time.
Focused Biopharmaceutical Strategy And PipelineDivesting iovera concentrates resources on biopharmaceutical assets while providing upfront and potential milestone funding. PCRX-201 progress and additional readouts create opportunities to diversify growth beyond the mature EXPAREL franchise.
Bears Say
Gross Margin CompressionA four-point margin decline reduces the amount of revenue converted into operating cash and profit. Expected higher-cost inventory and shutdown-related costs in Q4 indicate that margin pressure may persist beyond a single reporting period.
Exposure To Elective Procedure DemandPacira depends substantially on surgical and orthopedic procedure volumes, making utilization sensitive to changes in care settings and hospital demand. Weakness in elective inpatient procedures can limit product growth even when clinical value and access remain intact.
Volatile And Thin ProfitabilityInconsistent earnings make it harder to assess sustainable returns and can constrain reinvestment if operating costs rise faster than revenue. Thin current margins leave limited protection against pricing, product mix, procedure-volume or development-spending pressure.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira’s price range in the past 12 months?
Pacira lowest stock price was $18.80 and its highest was $27.66 in the past 12 months.
What is Pacira’s market cap?
Pacira’s market cap is $983.39M.
When is Pacira’s upcoming earnings report date?
Pacira’s upcoming earnings report date is Oct 29, 2026 which is in 65 days.
How were Pacira’s earnings last quarter?
Pacira released its earnings results on Aug 04, 2026. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.646 by $0.084.
Is Pacira overvalued?
According to Wall Street analysts Pacira’s price is currently Undervalued.
Does Pacira pay dividends?
Pacira does not currently pay dividends.
What is Pacira’s EPS estimate?
Pacira’s EPS estimate is 0.71.
How many shares outstanding does Pacira have?
Pacira has 39,861,885 shares outstanding.
What happened to Pacira’s price movement after its last earnings report?
Pacira reported an EPS of $0.73 in its last earnings report, beating expectations of $0.646. Following the earnings report the stock price went down -9.957%.
Which hedge fund is a major shareholder of Pacira?
Currently, no hedge funds are holding shares in PCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.80 (11.28% Upside)
$28.80 (11.28% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 21.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.08%
Trailing 12-Months
Company Description
Pacira
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted solid financial performance (6% revenue growth, robust adjusted EBITDA, strong cash position), meaningful commercial progress (major payer wins covering ~150M lives, EXPAREL and ZILRETTA momentum), important pipeline and manufacturing milestones (PCRX-201 manufacturing, multiple imminent readouts), and a strategic portfolio move (iovera divestiture with up to $140M consideration). Key challenges include softness in elective inpatient soft tissue procedures driven by macroeconomic factors, a decline in gross margin versus prior year, higher R&D and SG&A spend, and modest near-term moderation in EXPAREL volume growth. Overall, the positives — including clear payer wins, pipeline catalysts, cash generation, and strategic partnerships — outweigh the operational and margin headwinds.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$28.80
▲(11.28% Upside)
Technical Analysis
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―
Ownership Overview
3.67% Insiders
24.57% Mutual Funds
21.60% Other Institutional Investors
16.58% Public Companies and
Individual Investors